254 related articles for article (PubMed ID: 30037277)
1. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
Sidorkiewicz I; Zbucka-Krętowska M; Zaręba K; Lubowicka E; Zajkowska M; Szmitkowski M; Gacuta E; Ławicki S
BMC Cancer; 2019 Apr; 19(1):398. PubMed ID: 31035945
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
Zajkowska M; Gacuta E; Kozłowska S; Lubowicka E; Głażewska EK; Chrostek L; Szmitkowski M; Pawłowski P; Zbucka-Krętowska M; Ławicki S
Adv Med Sci; 2019 Mar; 64(1):1-8. PubMed ID: 30227310
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.
Lubowicka E; Zbucka-Kretowska M; Sidorkiewicz I; Zajkowska M; Gacuta E; Puchnarewicz A; Chrostek L; Szmitkowski M; Ławicki S
Pathol Oncol Res; 2020 Apr; 26(2):791-800. PubMed ID: 30820752
[TBL] [Abstract][Full Text] [Related]
6. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Biomarkers; 2017 Mar; 22(2):157-164. PubMed ID: 27775427
[TBL] [Abstract][Full Text] [Related]
8. [The plasma levels and diagnostic utility of matrix metalloproteinase-9 and CA 125 in cervical cancer patients].
Lubowicka E; Gacuta E; Zajkowska M; Głażewska EK; Przylipiak A; Chrostek L; Zbucka-Krętowska M; Ławicki S
Pol Merkur Lekarski; 2017 Jul; 43(253):10-14. PubMed ID: 28805195
[TBL] [Abstract][Full Text] [Related]
9. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients.
Porika M; Vemunoori AK; Tippani R; Mohammad A; Bollam SR; Abbagani S
Asian Pac J Cancer Prev; 2010; 11(6):1745-7. PubMed ID: 21338226
[TBL] [Abstract][Full Text] [Related]
10. Serum expression level of squamous cell carcinoma antigen, highly sensitive C-reactive protein, and CA-125 as potential biomarkers for recurrence of cervical cancer.
Guo S; Yang B; Liu H; Li Y; Li S; Ma L; Liu J; Guo W
J Cancer Res Ther; 2017; 13(4):689-692. PubMed ID: 28901315
[TBL] [Abstract][Full Text] [Related]
11. Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
Sidorkiewicz I; Piskór B; Dąbrowska E; Guzińska-Ustymowicz K; Pryczynicz A; Zbucka-Krętowska M; Ławicki S
Anticancer Res; 2019 Nov; 39(11):6403-6412. PubMed ID: 31704874
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients.
Mroczko B; Kozłowski M; Groblewska M; Łukaszewicz M; Nikliński J; Jelski W; Laudański J; Chyczewski L; Szmitkowski M
Clin Chim Acta; 2008 Mar; 389(1-2):61-6. PubMed ID: 18155162
[TBL] [Abstract][Full Text] [Related]
13. Serum CCAT2 as a biomarker for adjuvant diagnosis and prognostic prediction of cervical cancer.
Cao X; Yao J; Jia M; Shen X; Zhang J; Ju S
J Ovarian Res; 2022 Feb; 15(1):20. PubMed ID: 35115025
[TBL] [Abstract][Full Text] [Related]
14. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
[TBL] [Abstract][Full Text] [Related]
15. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer.
Zajkowska M; Lubowicka E; Malinowski P; Szmitkowski M; Ławicki S
Acta Biochim Pol; 2018 Dec; 65(4):621-628. PubMed ID: 30543720
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of serum metalloproteinase 9 in patients with esophageal squamous cell carcinoma.
Łukaszewicz-Zajac M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Szmitkowski M
Pol Arch Med Wewn; 2009 Sep; 119(9):558-63. PubMed ID: 19776700
[TBL] [Abstract][Full Text] [Related]
18. [Tumor makrers in cervical cancer].
Markowska J
Ginekol Pol; 2007 Sep; 78(9):715-8. PubMed ID: 18159826
[TBL] [Abstract][Full Text] [Related]
19. Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis.
Xu L; Bian W; Gu XH; Shen C
COPD; 2017 Apr; 14(2):245-250. PubMed ID: 28128990
[TBL] [Abstract][Full Text] [Related]
20. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Clin Lab; 2016 Sep; 62(9):1661-1669. PubMed ID: 28164586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]